Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři	DOUBEK Michael BRYCHTOVÁ Yvona PANOVSKÁ Anna ŠEBEJOVÁ Ludmila STEHLÍKOVÁ Olga CHOVANCOVÁ Jana MALČÍKOVÁ Jitka ŠMARDOVÁ Jana PLEVOVÁ Karla VOLFOVÁ Pavlína TRBUŠEK Martin MRÁZ Marek BAKEŠOVÁ Denisa TRIZULJAK Jakub HADRABOVÁ Markéta OBRTLÍKOVÁ Petra KARBAN Josef SMOLEJ Lukáš OLTOVÁ Alexandra JELÍNKOVÁ Eva POSPÍŠILOVÁ Šárka MAYER Jiří
Rok publikování	2015
Druh	Článek v odborném periodiku
Časopis / Zdroj	American Journal of Hematology
Fakulta / Pracoviště MU	Středoevropský technologický institut
Citace
www	http://onlinelibrary.wiley.com/doi/10.1002/ajh.23964/epdf
Doi	http://dx.doi.org/10.1002/ajh.23964
Obor	Onkologie a hematologie
Klíčová slova	HIGH-DOSE METHYLPREDNISOLONE; RITUXIMAB; COMBINATION; FLUDARABINE; IBRUTINIB; EFFICACY; THERAPY; CD20
Přiložené soubory	1299395_Ofatumumab_added_Doubek_et_al-2015-American_Journal_of_Hematology.pdf ZVV_2015_022_1299395_Ofatumumab.pdf
Popis	The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and toxicity of an ofatumumab-dexamethasone (O-Dex) combination in relapsed or refractory CLL. The trial was an open-label, multicenter, nonrandomized, Phase II study. The O-Dex regimen consisted of intravenous ofatumumab (Cycle 1: 300 mg on day 1, 2,000 mg on days 8, 15, and 22; Cycles 2-6: 1,000 mg on days 1, 8, 15, and 22) and oral dexamethasone (40 mg on days 1-4 and 15-18; Cycles 1-6). The O-Dex regimen was given until best response, or a maximum of six cycles. Thirty-three patients (pts) were recruited. Twenty-four (73%) pts completed at least three cycles of therapy. The remaining nine pts were prematurely discontinued owing to Grade 3/4 infections (seven pts), disease progression (one pt), or uncontrollable diabetes mellitus (one pt). Overall response rates/complete remissions (ORR/CR) were achieved in 22/5 pts (67/15%). The median progression-free survival (PFS) was 10 months. In pts with p53 defects (n=8), ORR/CR were achieved in 5/2 pts (63/25%) with a median PFS of 10.5 months. The median overall survival (OS) was 34 months. The Grades 3-5 infectious toxicity in 33% of pts represented the most frequent side effect during the treatment period. In conclusion, the O-Dex regimen shows a relatively high ORR and CR with promising findings for PFS and OS. The study was registered at (NCT01310101). Am. J. Hematol. 90:417-421, 2015. (c) 2015 Wiley Periodicals, Inc.